RIGEL PHARMACEUTICALS, INC. Net Income
RIGEL PHARMACEUTICALS, INC. (RIGL) reported Net Income of $17.29 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-08-04
- RIGEL PHARMACEUTICALS, INC. net income (loss) attributable to parent for the quarter ending 2026-06-30 was $17.29M, a 71.00% decline year-over-year.
- RIGEL PHARMACEUTICALS, INC. net income (loss) attributable to parent for the quarter ending 2026-03-31 was $8.65M, a 24.39% decline year-over-year.
- RIGEL PHARMACEUTICALS, INC. net income (loss) attributable to parent for the quarter ending 2025-12-31 was $268.06M, a 1769.22% increase year-over-year.
- RIGEL PHARMACEUTICALS, INC. net income (loss) attributable to parent for the quarter ending 2025-09-30 was $27.90M, a 124.62% increase year-over-year.
- RIGEL PHARMACEUTICALS, INC. net income (loss) attributable to parent for fiscal 2025 was $367.02M, a 1999.08% increase from fiscal 2024.
- RIGEL PHARMACEUTICALS, INC. net income (loss) attributable to parent for fiscal 2024 was $17.48M.
- RIGEL PHARMACEUTICALS, INC. net income (loss) attributable to parent for fiscal 2023 was -$25.09M.
- RIGEL PHARMACEUTICALS, INC. net income (loss) attributable to parent for fiscal 2022 was -$58.57M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | $17.29M 10-Q · filed 2026-08-04 | $25.94M 10-Q · filed 2026-08-04 | $294.01M derived: sum of 3 quarters · filed 2026-08-04 | $321.91M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $8.65M 10-Q · filed 2026-08-04 | $276.72M derived: sum of 2 quarters · filed 2026-08-04 | $304.62M derived: sum of 3 quarters · filed 2026-08-04 | $364.23M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $268.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $295.96M derived: sum of 2 quarters · filed 2026-03-03 | $355.58M derived: sum of 3 quarters · filed 2026-08-04 | $367.02M 10-K · filed 2026-03-03 |
| 2025-09-30 | $27.90M 10-Q · filed 2025-11-04 | $87.51M derived: sum of 2 quarters · filed 2026-08-04 | $98.96M 10-Q · filed 2025-11-04 | $113.30M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $59.61M 10-Q · filed 2026-08-04 | $71.06M 10-Q · filed 2026-08-04 | $85.40M derived: sum of 3 quarters · filed 2026-08-04 | $97.82M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $11.45M 10-Q · filed 2026-08-04 | $25.79M derived: sum of 2 quarters · filed 2026-08-04 | $38.21M derived: sum of 3 quarters · filed 2026-08-04 | $37.18M derived: sum of 4 quarters · filed 2026-08-04 |
| 2024-12-31 | $14.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $26.76M derived: sum of 2 quarters · filed 2026-03-03 | $25.73M derived: sum of 3 quarters · filed 2026-03-03 | $17.48M 10-K · filed 2026-03-03 |
| 2024-09-30 | $12.42M 10-Q · filed 2025-11-04 | $11.39M derived: sum of 2 quarters · filed 2025-11-04 | $3.14M 10-Q · filed 2025-11-04 | $3.88M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-06-30 | -$1.03M 10-Q · filed 2025-08-05 | -$9.28M 10-Q · filed 2025-08-05 | -$8.54M derived: sum of 3 quarters · filed 2026-03-03 | -$14.23M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-03-31 | -$8.25M 10-Q · filed 2025-05-06 | -$7.51M derived: sum of 2 quarters · filed 2026-03-03 | -$13.20M derived: sum of 3 quarters · filed 2026-03-03 | -$19.80M derived: sum of 4 quarters · filed 2026-03-03 |
| 2023-12-31 | $737.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$4.96M derived: sum of 2 quarters · filed 2026-03-03 | -$11.55M derived: sum of 3 quarters · filed 2026-03-03 | -$25.09M 10-K · filed 2026-03-03 |
| 2023-09-30 | -$5.69M 10-Q · filed 2024-11-07 | -$12.29M derived: sum of 2 quarters · filed 2024-11-07 | -$25.83M 10-Q · filed 2024-11-07 | -$24.43M derived: sum of 4 quarters · filed 2025-03-04 |
| 2023-06-30 | -$6.60M 10-Q · filed 2024-08-06 | -$20.14M 10-Q · filed 2024-08-06 | -$18.73M derived: sum of 3 quarters · filed 2025-03-04 | -$37.77M derived: sum of 4 quarters · filed 2025-03-04 |
| 2023-03-31 | -$13.54M 10-Q · filed 2024-05-07 | -$12.13M derived: sum of 2 quarters · filed 2025-03-04 | -$31.17M derived: sum of 3 quarters · filed 2025-03-04 | -$44.66M derived: sum of 4 quarters · filed 2025-03-04 |
| 2022-12-31 | $1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | -$17.64M derived: sum of 2 quarters · filed 2025-03-04 | -$31.13M derived: sum of 3 quarters · filed 2025-03-04 | -$58.57M 10-K · filed 2025-03-04 |
| 2022-09-30 | -$19.04M 10-Q · filed 2023-11-07 | -$32.53M derived: sum of 2 quarters · filed 2023-11-07 | -$59.97M 10-Q · filed 2023-11-07 | -$82.61M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-06-30 | -$13.49M 10-Q · filed 2023-08-01 | -$40.94M 10-Q · filed 2023-08-01 | -$63.58M derived: sum of 3 quarters · filed 2024-03-05 | -$84.53M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-03-31 | -$27.45M 10-Q · filed 2023-05-02 | -$50.09M derived: sum of 2 quarters · filed 2024-03-05 | -$71.04M derived: sum of 3 quarters · filed 2024-03-05 | -$84.86M derived: sum of 4 quarters · filed 2024-03-05 |
| 2021-12-31 | -$22.64M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | -$43.59M derived: sum of 2 quarters · filed 2024-03-05 | -$57.41M derived: sum of 3 quarters · filed 2024-03-05 | -$17.91M 10-K · filed 2024-03-05 |
| 2021-09-30 | -$20.95M 10-Q · filed 2022-11-03 | -$34.77M derived: sum of 2 quarters · filed 2022-11-03 | $4.73M 10-Q · filed 2022-11-03 | -$14.51M derived: sum of 4 quarters · filed 2023-03-07 |
| 2021-06-30 | -$13.82M 10-Q · filed 2022-08-02 | $25.68M 10-Q · filed 2022-08-02 | $6.44M derived: sum of 3 quarters · filed 2023-03-07 | -$7.73M derived: sum of 4 quarters · filed 2023-03-07 |
| 2021-03-31 | $39.50M 10-Q · filed 2022-05-03 | $20.26M derived: sum of 2 quarters · filed 2023-03-07 | $6.09M derived: sum of 3 quarters · filed 2023-03-07 | |
| 2020-12-31 | -$19.24M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | -$33.41M derived: sum of 2 quarters · filed 2023-03-07 | -$29.74M 10-K · filed 2023-03-07 | |
| 2020-09-30 | -$14.17M 10-Q · filed 2021-11-02 | -$10.51M 10-Q · filed 2021-11-02 | ||
| 2019-12-31 | -$66.89M 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |